Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Dendreon Corporation today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline.

7 Jan 2011

World's largest medical robotic conference

The International Robotic Urology Symposium 2011 is hosted by the Henry Ford Vattikuti Urology Institute and the Vattikuti Foundation.

7 Jan 2011

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

Elevated fat and cholesterol levels found in a typical American-style diet play an important role in the growth and spread of breast cancer, say researchers at the Kimmel Cancer Center at Jefferson.

7 Jan 2011

NCCN Guidelines provide treatment information for patients with melanoma, prostate and ovarian cancer

People with melanoma, ovarian cancer, or prostate cancer now have a new resource that provides them with the same credible information their physicians use when determining treatment options. The National Comprehensive Cancer Network announces three new additions to the library of NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

6 Jan 2011

Physical activity associated with lower risk of death for prostate cancer patients: Study

A new study of men with prostate cancer finds that physical activity is associated with a lower risk of overall mortality and of death due to prostate cancer. The Harvard School of Public Health and University of California, San Francisco researchers also found that men who did more vigorous activity had the lowest risk of dying from the disease.

6 Jan 2011

EUSA receives FDA Priority Review status for ERWINAZE BLA

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that its Biologics License Application for ERWINAZE(R) has been accepted for filing and awarded Priority Review status by the U.S. Food and Drug Administration.

5 Jan 2011

Single cancer cell could be detected in future using new test

Soon scientists will be able to detect a single cancer cell among the billions of cells that circulate in the human bloodstream. The method could detect whether the therapy has worked or even show which therapy would work best. The test depends on circulating tumor cells (CTCs) or cancer cells that have detached from the main tumor and are traveling to other parts of the body.

4 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

EDAP reduces outstanding debt by $4.6 million

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today that it entered into agreements with certain holders of its senior debentures and warrants to redeem part of EDAP's outstanding convertible debt and cancel some of its outstanding warrants. Pursuant to these agreements, the Company issued 1,441,743 ordinary shares in the form of American Depositary Shares in exchange for 4,558 senior debentures (equivalent to USD 4,558,000) and 986,965 warrants, reducing the current outstanding debt by USD 4.6 million to USD 10.5 million.

3 Jan 2011

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010

U.S judge awards $11.7 million to DF/HCC for large-scale prostrate cancer research

Dana Farber/Harvard Cancer Center will launch a new multi-million dollar grant award program focused on prostate cancer research. It will be administered in collaboration with the Prostate Cancer Foundation.

28 Dec 2010

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

USPTO validates Spectros white LED patent during reexamination

A core Spectros white LED patent was validated during reexamination by the United States Patent Office, and will reissue next year.

22 Dec 2010

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

The day when an ovarian cancer patient can treat her tumor with a single, painless pill instead of a toxic drug cocktail is the ultimate goal of the pioneering research of a University of Houston scientist.

22 Dec 2010

Men above age 75 with high-risk prostate cancer often under-treated

Older men with high-risk prostate cancer frequently are offered fewer - and less effective - choices of treatment than younger men, potentially resulting in earlier deaths, according to a new UCSF study.

22 Dec 2010

Wyden's cancer treatment highlights debate over health care cost vs. personal choice

Sen. Ron Wyden had surgery for prostate cancer Monday, putting himself — through no fault of his own — in the middle of a debate about diagnosis, treatment and bending the cost curve.

22 Dec 2010

Chronic fatigue syndrome not linked to virus

The latest research from the University College London, the Wellcome Trust Sanger Institute, and University of Oxford, England suggests that chronic fatigue syndrome (CFS) is not caused by the virus XMRV (xenotropic murine leukemia virus-related virus). The team says that earlier research that linked the virus to CFS was faulty because of contamination of mouse cell DNA samples in the laboratory.

21 Dec 2010

U of A student wins annual master's thesis competition for research on light-sensitive drug for prostate cancer

The future of cancer treatment and a University of Alberta graduate student's personal career prospects are looking bright. Weiyang Liu beat competitors from 80 of the best university graduate schools in western North America with his master's thesis on the use of a light-sensitive drug to treat prostate cancer.

20 Dec 2010

Researchers demonstrate that monensin antibiotic prevents prostate cancer cell growth

Researchers from VTT Technical Research Centre of Finland and the University of Turku have demonstrated that an antibiotic called "monensin" prevents the growth of prostate cancer cells. Monensin is used in the meat and dairy industry, for example.

20 Dec 2010

Study: Biomarkers may aid in early diagnosis of breast cancer

Using a new, powerful method for rapidly screening molecules associated with disease, proteomics expert Joshua LaBaer and colleagues from the Biodesign Institute at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may one day aid in the early diagnosis of breast cancer.

17 Dec 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

World's largest medical robotic conference

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

NCCN Guidelines provide treatment information for patients with melanoma, prostate and ovarian cancer

Physical activity associated with lower risk of death for prostate cancer patients: Study

EUSA receives FDA Priority Review status for ERWINAZE BLA

Single cancer cell could be detected in future using new test

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

EDAP reduces outstanding debt by $4.6 million

FDA approves Endo's FORTESTA Gel for low testosterone

U.S judge awards $11.7 million to DF/HCC for large-scale prostrate cancer research

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

USPTO validates Spectros white LED patent during reexamination

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

Men above age 75 with high-risk prostate cancer often under-treated

Wyden's cancer treatment highlights debate over health care cost vs. personal choice

Chronic fatigue syndrome not linked to virus

U of A student wins annual master's thesis competition for research on light-sensitive drug for prostate cancer

Researchers demonstrate that monensin antibiotic prevents prostate cancer cell growth

Study: Biomarkers may aid in early diagnosis of breast cancer

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in